



ORIGINAL ARTICLE

Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis



Carlos Galvão Braga*, Vítor Ramos, Juliana Martins, Carina Arantes,
Glória Abreu, Catarina Vieira, Alberto Salgado, António Gaspar, Pedro Azevedo,
Miguel Álvares Pereira, Sónia Magalhães, Jorge Marques

Serviço de Cardiologia, Hospital de Braga, Braga, Portugal

Received 17 June 2014; accepted 1 January 2015

Available online 29 May 2015

KEYWORDS

Atrial fibrillation;
Acute coronary
syndrome;
Prognosis

Abstract

Introduction: Atrial fibrillation (AF) is widely recognized as an adverse prognostic factor during acute myocardial infarction, although the impact of AF type – new-onset (nAF) or pre-existing (pAF) – is still controversial.

Objectives: To identify the clinical differences and prognosis of nAF and pAF during acute coronary syndromes (ACS).

Methods: We performed a retrospective observational cohort study including 1373 consecutive patients (mean age 64 years, 77.3% male) admitted to a single center over a three-year period, with a six-month follow-up.

Results: AF rhythm was identified in 14.5% patients, of whom 71.4% presented nAF and 28.6% pAF. When AF types were compared, patients with nAF more frequently presented with ST-elevation ACS ($p=0.003$). Patients with pAF, in turn, were older ($p=0.032$), had greater left atrial diameter ($p=0.001$) and were less likely to have significant coronary lesions ($p=0.034$). Regarding therapeutic strategy, nAF patients were more often treated by rhythm control during hospital stay ($p<0.001$) and were less often anticoagulated at discharge ($p=0.001$). Compared with the population without AF, nAF was a predictor of death during hospital stay in univariate ($p<0.001$) and multivariate analysis (OR 2.67, $p=0.047$), but pAF was not. During follow-up, pAF was associated with higher mortality ($p=0.014$), while nAF patients presented only a trend towards worse prognosis.

Conclusions: AF during the acute phase of ACS appears to have a negative prognostic impact only in patients with nAF and not in those with pAF.

© 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: carlos.galvaobraga@gmail.com (C.G. Braga).

PALAVRAS-CHAVE

Fibrilhação auricular;
Síndrome coronária
aguda;
Prognóstico

Impacto do tipo de fibrilhação auricular no contexto das síndromes coronárias agudas – características clínicas e prognóstico

Resumo

Introdução: A fibrilhação auricular (FA) é um reconhecido fator de mau prognóstico no enfarte agudo do miocárdio, no entanto, o impacto do tipo de FA, *de novo* (FAn) ou pré-existente (FAp), é ainda controverso.

Objetivos: Identificar as diferenças clínicas e o prognóstico da FAn e da FAp nas síndromes coronárias agudas (SCA).

Métodos: Estudo retrospectivo observacional de coorte, incluindo 1373 doentes consecutivos (idade média 64 anos, 77,3% homens) com SCA, admitidos num hospital, ao longo de três anos, com *follow-up* de seis meses.

Resultados: A FA foi identificada em 14,5% doentes, dos quais 71,4% tinham FAn e 28,6% FAp. Comparando os tipos de FA, verificou-se que os doentes com FAn apresentaram mais frequentemente SCA com elevação do segmento ST ($p=0,003$). Por sua vez, a FAp foi mais comum em doentes idosos ($p=0,032$), com diâmetro superior da aurícula esquerda ($p=0,001$) e ausência de doença coronária ($p=0,034$). Quanto à estratégia terapêutica, os doentes com FAn foram mais vezes submetidos a controlo de ritmo durante o internamento ($p<0,001$), mas menos hipocogulados à alta ($p=0,001$). Quando comparada com a população sem FA, a FAn foi preditora de morte hospitalar na análise univariada ($p<0,001$) e multivariada (OR 2,67, $p=0,047$), enquanto a FAp não. Já no *follow-up*, a FAp associou-se a maior mortalidade ($p=0,014$), enquanto os doentes com FAn apresentaram apenas uma tendência para um pior prognóstico.

Conclusões: O impacto prognóstico negativo da FA na fase aguda das SCA parece ocorrer apenas nos doentes que apresentam FAn e não naqueles com FAp.

© 2014 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

Introduction

Atrial fibrillation (AF) frequently complicates the clinical course of acute myocardial infarction (AMI), with a reported incidence between 6 and 21%.¹ Although this arrhythmia is a well-established independent predictor of mortality in the short and long term after AMI,^{2–4} the impact of the specific AF type – new-onset or pre-existing – may be different. Few published studies have been conducted regarding this question and the results are conflicting.^{2,5–11} In a recent meta-analysis, Angeli et al.¹² showed that AF in the setting of AMI was associated with a two-fold higher risk of in-hospital mortality, but the risk of death was 87% higher in patients with new-onset AF than in those with permanent AF.

The primary aim of this study was to identify the clinical differences and prognostic impact of AF type during acute coronary syndromes (ACS).

Methods

This was a retrospective observational cohort study with a six-month follow-up. All patients ($n=1373$; mean age 64 years, 77.3% male) consecutively admitted to the coronary care unit of a single center with a diagnosis of ACS between July 2009 and June 2012 were included.

Diagnoses of ACS and AF were made according to the European Society of Cardiology guidelines.^{13–16} Heart failure was defined as Killip class ≥ 2 during hospitalization and

as NYHA class ≥ 2 during follow-up. Patients with AF were divided according to the timing of the arrhythmia: every patient who presented with AF for the first time (i.e., who did not have previously documented AF) at admission or during hospital stay was considered to have new-onset AF, while those with previously documented AF were classified as having pre-existing AF (paroxysmal, persistent or permanent).

Regarding AF management, a rhythm control strategy was defined as the aim of restoration and successful maintenance of sinus rhythm and rate control strategy as acceptance of AF rhythm with ventricular rate control. The use of oral anticoagulation and antiarrhythmic therapy (amiodarone) at discharge was also assessed. The management of each patient was individualized and based on clinical parameters.

Demographic, clinical, laboratory, echocardiographic and coronary angiographic data were collected prospectively and recorded in a computerized database, in accordance with our department's protocol for patients admitted to the coronary care unit with ACS.

Concerning laboratory data, N-terminal pro-brain natriuretic peptide (NT-proBNP) values were obtained within 24 hours of admission and peak creatinine was considered to be the maximum value during hospitalization. Glomerular filtration rate was calculated at presentation using the abbreviated Modification of Diet in Renal Disease formula.¹⁷

The first echocardiogram performed in hospital was used to provide echocardiographic data. Right ventricular systolic dysfunction was defined as tricuspid annular systolic excursion >16 mm.

Coronary angiographic data were collected from angiography performed during hospital stay. Significant coronary artery disease on coronary angiography was defined as at least one $\geq 50\%$ lesion in the left main artery and/or $\geq 70\%$ in other coronary arteries. Multivessel disease was defined as significant stenosis in two or more major epicardial arteries and coronary revascularization as successful percutaneous or surgical coronary intervention to restore blood flow.

Statistical analysis

Univariate analysis of categorical variables was performed using the chi-square test, with results expressed as percentages, and of continuous variables using the Student's *t* test, with results expressed as means \pm standard deviation. Analysis of the therapeutic strategy used to manage AF was performed after exclusion of patients who died during hospital stay. Multivariate logistic analysis was performed to determine the independent predictors of in-hospital mortality, including only variables with statistical significance on univariate analysis. Kaplan-Meier analysis was used to illustrate six-month cumulative mortality according to the presence of AF and AF type. Differences with $p < 0.05$ were considered significant. The statistical analysis was carried out using SPSS version 18.0.

Results

In the study population ($n=1373$), AF rhythm was identified in 14.5% patients ($n=199$), of whom 71.4% ($n=142$) presented new-onset AF and 28.6% ($n=57$) pre-existing AF. Patients with new-onset AF, pre-existing AF and without AF were studied according to their baseline characteristics, in-hospital features and clinical outcomes.

Baseline characteristics and in-hospital data

New-onset AF and pre-existing AF patients were compared with those without AF. The baseline characteristics of the study population are shown in Table 1.

AF, either new-onset or pre-existing, was more frequent in older, non-smoking and hypertensive patients. Although the proportion of women was higher in both AF types than in patients without AF, the difference was only significant for those with pre-existing AF ($p=0.015$). AF patients had greater cardiovascular disease burden and were more likely to be taking cardiovascular medication at presentation, as demonstrated in Table 1.

Clinical information during hospital stay and laboratory, echocardiographic, coronary angiographic and revascularization data are summarized in Table 2.

At admission, patients with new-onset and pre-existing AF had higher heart rate and worse Killip class. No differences were found in systolic blood pressure. Interestingly, ACS severity was related to AF type: ST-elevation ACS incidence was higher in new-onset AF (60.1%, $p=0.030$), intermediate in the AF-free group (50.6%) and lower in pre-existing AF (36.8%, $p=0.043$).

During hospitalization, the presence of AF, regardless of type, was associated with worse clinical, laboratory and echocardiographic features. Patients with AF were more

likely to have heart failure, lower glomerular filtration rate, higher peak creatinine, lower hemoglobin and higher NT-proBNP. Additionally, patients with AF more often presented biventricular systolic dysfunction, higher mitral regurgitation grade and greater left atrial diameter. Although the incidence of respiratory tract infections was higher in AF groups, only new-onset AF patients had significantly higher C-reactive protein levels than patients without AF. No differences between non-AF and AF groups were found regarding other arrhythmic complications, such as high grade atrioventricular block or ventricular fibrillation.

The presence of multivessel disease was similar between groups. Patients with new-onset AF and pre-existing AF were less likely to have significant coronary lesions or to have undergone coronary revascularization, the latter due to the lower number of percutaneous coronary interventions (PCI) performed.

The thromboembolic risk score CHA₂DS₂VASc and the GRACE score were higher in patients with new-onset and pre-existing AF than in patients without AF.

Comparison between atrial fibrillation types

The clinical and in-hospital differences with statistical significance between new-onset AF and pre-existing AF groups are displayed in Table 3. Patients with new-onset AF were younger ($p=0.044$), more often smokers ($p=0.015$) and had higher body mass index ($p=0.003$). Concerning medication at admission, naturally, patients with pre-existing AF were more frequently taking anticoagulants ($p<0.001$) and renin-angiotensin system modulators ($p=0.023$). As pointed out earlier, in contrast to pre-existing AF, the majority of new-onset AF patients presented with ST-elevation ACS (60.1% vs. 36.8%, respectively, $p=0.003$). Although left atrial enlargement was common in both AF types, left atrial diameter on echocardiography was significantly greater in pre-existing AF ($p=0.001$). In coronary angiography, absence of significant coronary artery disease was observed more in pre-existing AF ($p=0.034$).

Regarding management strategies, new-onset AF patients were more often treated by rhythm control during hospital stay ($p<0.001$) than pre-existing AF patients, as shown in Table 4. Patients with pre-existing AF treated by rhythm control were more likely to be prescribed antiarrhythmic therapy to maintain sinus rhythm, although without significance. At discharge, new-onset AF patients were less often anticoagulated than those with pre-existing AF ($p<0.001$).

Prognostic impact of atrial fibrillation type

New-onset AF was associated with significantly worse in-hospital adverse outcomes of death, heart failure, ischemic stroke and major bleeding compared to patients with no arrhythmia, as demonstrated in Table 5. Except for heart failure, such associations were not present in the group with pre-existing AF.

Together with glomerular filtration rate in ml/min/1.73 m² (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.95–0.99, $p=0.010$), heart failure (OR 3.80, 95% CI 1.22–11.86, $p=0.022$) and ventricular fibrillation (OR 5.42, 95% CI 1.29–22.87, $p=0.021$), new-onset AF remained an

Table 1 Baseline clinical characteristics of patients without AF compared with those with new-onset and pre-existing AF.

	Without AF (n=1174)	New-onset AF (n=142)	p	Pre-existing AF (n=57)	p
<i>Demographics</i>					
Age (years), mean (SD)	63 (±13)	72 (±12)	<0.001	75 (±10)	<0.001
Male, %	78.6%	71.8%	0.066	64.9%	0.015
BMI (kg/m ²), mean (SD)	27.3 (±4.0)	28.2 (±4.9)	0.053	26.4 (±3.2)	0.073
<i>CV risk factors, %</i>					
Hypertension	61.8%	80.3%	<0.001	87.7%	<0.001
Diabetes	26.3%	32.4%	0.123	21.1%	0.376
Dyslipidemia	55.1%	55.6%	0.906	49.1%	0.375
Smoking	31.3%	16.2%	<0.001	3.5%	<0.001
<i>History, %</i>					
AMI	14.6%	21.1%	0.040	19.3%	0.326
CABG	3.7%	8.5%	0.009	3.5%	0.926
PCI	8.1%	6.3%	0.464	3.5%	0.210
Stroke	6.6%	10.6%	0.077	17.5%	0.002
<i>Previous medication, %</i>					
Anticoagulant	2.3%	2.2%	0.958	33.3%	<0.001
Aspirin	22.6%	38.0%	<0.001	40.4%	0.002
Clopidogrel	8.2%	9.9%	0.494	10.5%	0.530
ACEI/ARB	42.0%	56.3%	0.001	73.7%	<0.001
Beta-blocker	19.8%	26.8%	0.051	33.3%	0.013
Statin	34.8%	38.7%	0.354	42.1%	0.262
Diuretic	21.6%	36.3%	0.002	38.9%	0.015

ACEI: angiotensin-converting enzyme inhibitor; AF: atrial fibrillation; AMI: acute myocardial infarction; ARB: angiotensin receptor blocker; BMI: body mass index; CABG: coronary artery bypass grafting; CV: cardiovascular; PCI: percutaneous coronary intervention; SD: standard deviation.

independent predictor of in-hospital mortality, carrying a risk 2.67 times higher than in the group without AF (95% CI 1.01–7.02, $p=0.047$).

During follow-up (mean 218 ± 92 days), heart failure occurred more frequently in AF groups than in patients without AF. Mortality was higher in pre-existing ($p=0.014$) but not in new-onset AF, although the latter was associated with a trend towards higher mortality (6.3% vs. 3.6%, $p=0.155$). No differences were found regarding reinfarction or ischemic stroke during follow-up.

Kaplan-Meier survival curves (Figure 1) illustrate a trend towards worse prognosis for both AF groups compared with no arrhythmia, with significance for new-onset AF (log rank $p<0.001$) but not for pre-existing AF (log rank $p=0.120$).

Patients with new-onset AF discharged in sinus rhythm and followed in the outpatient clinic of our hospital ($n=33$) had a longer follow-up (mean 557 ± 381 days). The recurrence rate of AF in this subgroup during follow-up was 24.2% ($n=8$).

Discussion

Recently, our group reported that patients with new-onset AF in the context of ACS had worse clinical manifestations and adverse prognostic implications during hospitalization and throughout follow-up.¹⁸ Questions regarding the clinical features and prognostic impact of different AF types, new-onset or pre-existing, remained unanswered. The present




Figure 1 Kaplan-Meier survival curves for patients with new-onset AF, pre-existing AF and without AF. AF: atrial fibrillation.

study included a larger number of patients, allowing direct comparison between new-onset and pre-existing AF.

First, regardless of type, patients with AF presented high-risk clinical features during hospitalization, such as older age, heart and renal failure, respiratory tract infections, lower hemoglobin, higher NT-proBNP, biventricular dysfunction, significant mitral regurgitation, less coronary revascularization and higher GRACE risk score. The bulk of evidence clearly demonstrates that the presence of AF in itself during ACS is associated with worse

Table 2 Clinical, laboratory, echocardiographic, coronary angiographic, and revascularization data and risk scores during hospital stay of patients without AF compared with those with new-onset and pre-existing AF.

	Without AF (n=1174)	New-onset AF (n=142)	p	Pre-existing AF (n=57)	p
<i>Clinical, %</i>					
Heart rate (bpm) ^a , mean (SD)	75 (±17)	87 (±25)	<0.001	83 (±24)	0.025
SBP (mmHg) ^a , mean (SD)	129 (±27)	129 (±27)	0.846	135 (±30)	0.147
ST-elevation ACS	50.6%	60.1%	0.030	36.8%	0.043
Heart failure ^a	18.6%	43.0%	<0.001	50.9%	<0.001
<i>Respiratory tract infections</i>					
≥ grade 2 AV block	5.1%	21.6%	<0.001	17.1%	0.002
VF	6.1%	9.2%	0.167	8.8%	0.423
	4.1%	6.3%	0.214	3.5%	0.829
<i>Blood tests, mean (SD)</i>					
GFR <60 ml/min/1.73 m ² , % ^a	22.2%	38.7%	<0.001	43.9%	<0.001
Peak creatinine (mg/dl)	1.2 (±0.6)	1.6 (±1.1)	<0.001	1.6 (±0.9)	0.003
Hemoglobin (g/dl) ^a	13.9 (±2.1)	13.3 (±2.2)	0.001	13.4 (±2.1)	0.045
RDW (%) ^a	13.7 (±1.1)	13.7 (±1.2)	0.965	14.0 (±5.8)	0.698
NT-proBNP (pg/ml)	2601 (±5564)	4723 (±7757)	0.004	6430 (±5727)	<0.001
CRP (mg/l) ^a	16.1 (±31.9)	30.9 (±49.4)	0.001	19.3 (±26.0)	0.477
<i>Echocardiography</i>					
LVEF ≤40%, %	30.3%	52.5%	<0.001	50.9%	0.001
RV systolic dysfunction, %	11.5%	4.8%	<0.001	17.3%	<0.001
MR (grade >II/IV), %	3.9%	15.0%	<0.001	13.2%	0.001
LA diameter (mm), mean (SD)	41 (±5)	45 (±6)	<0.001	49 (±7)	<0.001
<i>Coronary angiography, %</i>					
Absence of significant CAD	3.2%	6.7%	0.040	16.7%	<0.001
Multivessel disease	56.9%	62.8%	0.226	50.0%	0.368
<i>Coronary revascularization, %</i>					
PCI	68.5%	55.1%	0.002	55.1%	0.049
CABG	14.2%	10.9%	0.286	10.2%	0.432
Total	82.7%	65.9%	<0.001	65.3%	0.002
<i>Risk scores</i>					
CHA ₂ DS ₂ VASc score	3.2 (±1.6)	4.3 (±1.6)	<0.001	4.6 (±1.3)	<0.001
GRACE score	139 (±42)	172 (±42)	<0.001	172 (±45)	<0.001

ACS: acute coronary syndrome; AF: atrial fibrillation; AV: atrioventricular; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CRP: C-reactive protein; GFR: glomerular filtration rate; LA: left atrial; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; NT-proBNP: N-terminal pro-brain natriuretic peptide; PCI: percutaneous coronary intervention; RDW: red blood cell distribution width; RV: right ventricular; SBP: systolic blood pressure; SD: standard deviation; VF: ventricular fibrillation.

^a At admission.

Table 3 Differences between new-onset AF and pre-existing AF.

	New-onset AF (n=142)	Pre-existing AF (n=57)	p
Age (years)	72 (±12)	75 (±10)	0.044
BMI (kg/m ²)	28.2 (±4.9)	26.4 (±3.2)	0.003
Smoking	16.2%	3.5%	0.015
Anticoagulant, at presentation	2.2%	33.3%	<0.001
ACEI/ARB, at presentation	56.3%	73.7%	0.023
ST-elevation ACS	60.1%	36.8%	0.003
LA diameter	45 (±6)	49 (±7)	0.001
Absence of significant CAD	6.7%	16.7%	0.034

ACEI: angiotensin-converting enzyme inhibitor; ACS: acute coronary syndrome; ARB: angiotensin receptor blocker; BMI: body mass index; CAD: coronary artery disease; LA: left atrial.

Table 4 Therapeutic strategy according to AF type.

	New-onset AF (n=126)	Pre-existing AF (n=55)	p
Rate control	29.4%	72.7%	<0.001
Rhythm control	70.6%	27.3%	<0.001
Antiarrhythmic at discharge	18.0%	40.0%	0.053
Anticoagulation at discharge	33.3%	60.0%	0.001

AF: atrial fibrillation.

Table 5 In-hospital and follow-up adverse outcomes: comparison between patients without AF with new-onset and pre-existing AF groups.

	Without AF (n=1174)	New-onset AF (n=142)	p	Pre-existing AF (n=57)	p
<i>In-hospital, %</i>					
Mortality	4.2%	11.3%	<0.001	3.5%	0.806
Heart failure	27.2%	57.0%	<0.001	64.9%	<0.001
Re-infarction	2.5%	2.8%	0.803	1.8%	0.732
Ischemic stroke	0.8%	2.8%	0.020	1.8%	0.418
Major bleeding	2.3%	6.7%	0.015	0.0%	0.360
<i>Follow-up, %</i>					
Mortality	3.6%	6.3%	0.155	10.6%	0.014
Heart failure	22.8%	41.0%	<0.001	50.0%	<0.001
Re-infarction	3.6%	4.1%	0.818	7.9%	0.177
Ischemic stroke	1.0%	2.1%	0.472	2.6%	0.818

AF: atrial fibrillation.

in-hospital outcomes.^{1,2,7,19,20} The pathophysiological mechanisms underlying this relation may differ according to the timing of the arrhythmia. It is well known that acute AF complicating ACS is proportional to the grade of ischemia and has a negative effect on coronary perfusion and cardiac hemodynamics,² and is a marker of larger area of necrosis.^{5,21} In contrast, pre-existing AF patients usually have greater cardiovascular disease burden and more structural heart disease owing to the longer duration of the arrhythmia.⁷ Indeed, in our study, patients with pre-existing AF were older, more likely to be taking cardiovascular medications at admission and had greater left atrial diameter on echocardiography than patients with new-onset AF.

Second, unlike in previous studies,^{5–7} the most frequently encountered type was new-onset AF, which was found in more than two-thirds of AF patients. This could be due to a bias related to the definition used, since patients without AF history who were admitted in AF rhythm were labeled as new-onset AF, although the timing in such cases could not be determined with certainty and, as such, they could have been misclassified. Regarding management, the majority of these patients promptly and successfully returned to sinus rhythm during hospitalization, which favors correct classification as new-onset AF.

Third, in our study, the main differences at presentation between AF types were related to ACS severity, left atrial diameter and coronary angiography details. As pointed out above,^{7,18} ST-segment elevation ACS is a predictor of new-onset AF, probably because the myocardial ischemic burden, and hence the arrhythmogenic substrate, are greater in this subgroup.⁹ The pathogenesis of AF in this context is multifactorial and may include atrial

ischemia or infarction, ventricular dysfunction, pericardial inflammation, acute hypoxia, ionic disturbances, and neurohormonal and autonomic nervous system activation.^{22–24} Left atrial diameter was significantly greater in pre-existing AF patients, reflecting the progressive atrial dilatation and myocardial remodeling that occurs with AF evolution. It may represent a marker of arrhythmia duration, acting as a substrate for AF initiation and maintenance.¹⁰ Significant coronary artery disease on coronary angiography was more often absent in both subtypes, although in a higher proportion in pre-existing AF patients. In fact, AF can predispose to AMI without atherosclerotic plaque rupture through two mechanisms: coronary occlusion by a thromboembolic event or a mismatch between myocardial oxygen supply and demand caused by the elevated and irregular heart rate.^{14,25} We hypothesize that AF type might be a marker of the pathophysiologic mechanism underlying myocardial infarction: probably, acute plaque rupture is more common in new-onset AF and thromboembolism in pre-existing AF.

Fourth, short- and long-term prognosis differed according to AF type. New-onset AF conferred worse clinical outcomes and prognosis during hospital stay, while pre-existing AF was associated with mortality during follow-up, similar findings to the data published by Lau et al.⁷ The link between new-onset AF and ST-segment elevation ACS may in part explain the worse in-hospital prognosis. Unlike pre-existing AF, which does not imply an acute change in hemodynamic status and is therefore not associated with worse prognosis during hospitalization for ACS, new-onset AF acutely compromises hemodynamic status and, as such, implies worse clinical in-hospital course. In contrast, long-term mortality is higher in pre-existing AF, reflecting the existence of

chronic structural and functional heart disease.²⁶ Studies on the effect of AF type on prognosis after myocardial infarction show conflicting results.^{2,5-11} The heterogeneity of patients included in each study, and the substantial improvement in ACS treatment in recent years with the widespread use of PCI and the emergence of new drug therapies, could explain the dissimilarities in the clinical impact of AF type.

Finally, in our study, successful AF rhythm management predominated in patients with new-onset AF and rate control strategy was preferred in patients with pre-existing AF, as would be expected, since the latter were older and had larger left atrial diameter, recognized factors for AF recurrence, or were already on rate control for permanent AF. Regarding antithrombotic therapy at discharge, theoretically, patients with pre-existing AF should have been medicated with oral anticoagulation, since they all had CHA₂DS₂VASc scores ≥ 2 . Unlike primary AF, the anticipated bleeding risk is higher in post-ACS patients due to the concomitant use of dual antiplatelet therapy, which is recommended by the current guidelines for at least one month and ideally up to one year after ACS.¹³ While triple antithrombotic therapy appears to be safe and effective in the short term (30 days), prolonged triple therapy (one year) is associated with an excessive major bleeding risk.²⁷⁻²⁹ We reported that 40% of patients with pre-existing AF did not receive anticoagulation at discharge. The occurrence of bleeding complications during hospitalization and the presence of high bleeding risk were the main factors that precluded triple antithrombotic therapy. Lopes et al.,³⁰ in a large registry including 69 225 patients with AMI, found similar results, showing that fewer than 50% of patients with pre-existing AF received warfarin and only 14.6% were treated with triple antithrombotic therapy at discharge. In routine practice and in contrast to recommendations, older patients with AF and ACS who undergo PCI are more likely to receive dual antiplatelet therapy rather than triple antithrombotic therapy.^{31,32} In the WOEST trial,³³ the use of clopidogrel without aspirin in patients receiving concomitant oral anticoagulants and undergoing PCI was associated with a significant reduction in bleeding complications and no increase in the rate of thrombotic events within one year of intervention, posing the question whether high bleeding risk patients with ACS should be treated with single antiplatelet therapy plus anticoagulation. In our study, patients with new-onset AF were even less likely to be discharged with anticoagulation (only one third). In contrast to patients with pre-existing AF, the approach to anticoagulation in those with new-onset AF during ACS is far less clear. Studies report a non-negligible recurrence rate of new-onset AF that varies between 10 and 34%,³⁴⁻³⁷ a similar value to the 24.2% we described in the subgroup of patients discharged in sinus rhythm followed in our outpatient clinic. Asanin et al.³⁷ found that AF recurred more frequently soon after hospital discharge (<3 months) in patients who had longer duration AF episodes (>3.5 hours) within 48 hours of myocardial infarction. Furthermore, patients with new-onset AF are also more likely to suffer stroke during follow-up. Zusman et al.³⁵ reported an annual incidence of ischemic stroke of 4.4% vs. 0.2% in the non-AF group, and Siu et al.³⁴ found incidences of 10.2% and 7.5%, respectively, during the first and second year of follow-up, in patients with transient AF during

inferior AMI when they were treated with antiplatelet therapy alone. Asanin et al.³⁷ described some predictors of stroke in patients with a history of new-onset AF, including absence of anticoagulation at discharge, recurrence of AF and heart failure during follow-up. To summarize, although new-onset AF in the setting of ACS can be transient, it should not be regarded as a benign complication of the acute event, since it carries a substantial future risk for recurrence and stroke. Therefore, oral anticoagulation should also be strongly considered in patients with new-onset AF.

Limitations

There are several limitations to be considered in the interpretation of our study. First, this was a retrospective, observational and non-randomized study conducted at a single hospital, and as such, both identified and unidentified confounders may have influenced the outcomes. As pointed out above, new-onset AF patients could have been misclassified. Second, our results are limited by the relatively small numbers of patients studied with new-onset and pre-existing AF. Finally, most variables were determined by consulting medical records that could have been incomplete.

Conclusions

In summary, new-onset AF was more common in patients presenting with ST-elevation ACS who had high-risk clinical features and worse prognosis during hospitalization, probably reflecting a greater degree of ischemia. In turn, patients with pre-existing AF had greater mortality throughout follow-up, reflecting the existence of established structural heart disease.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Schmitt J, Duray G, Gersh BJ, et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence,

- clinical features and prognostic implications. *Eur Heart J*. 2009;30(9):1038–45.
2. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. *Circulation*. 2011;123(15):1587–93.
 3. Lopes RD, Pieper KS, Horton JR, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. *Heart*. 2008;94(7):867–73.
 4. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. *Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries*. *J Am Coll Cardiol*. 1997;30(2):406–13.
 5. Podolecki T, Lenarczyk R, Kowalczyk J, et al. Effect of type of atrial fibrillation on prognosis in acute myocardial infarction treated invasively. *Am J Cardiol*. 2012;109(12):1689–93.
 6. Maagh P, Butz T, Wickenbrock I, et al. New-onset versus chronic atrial fibrillation in acute myocardial infarction: differences in short- and long-term follow-up. *Clin Res Cardiol*. 2011;100(2):167–75.
 7. Lau DH, Huynh LT, Chew DP, et al. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. *Am J Cardiol*. 2009;104(10):1317–23.
 8. Poçi D, Hartford M, Karlsson T, et al. Effect of new versus known versus no atrial fibrillation on 30-day and 10-year mortality in patients with acute coronary syndrome. *Am J Cardiol*. 2012;110(2):217–21.
 9. Mehta RH, Dabbous OH, Granger CB, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. *Am J Cardiol*. 2003;92(9):1031–6.
 10. Lehto M, Snapinn S, Dickstein K, et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. *Eur Heart J*. 2005;26(4):350–6.
 11. Sakata K, Kurihara H, Iwamori K, et al. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. *Am J Cardiol*. 1997;80(12):1522–7.
 12. Angeli F, Reboldi G, Garofoli M, et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. *Curr Cardiol Rep*. 2012;14(5):601–10.
 13. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*. 2010;31(19):2369–429.
 14. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J*. 2012;33(20):2551–67.
 15. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32(23):2999–3054.
 16. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33(20):2569–619.
 17. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med*. 2006;145(4):247–54.
 18. Galvão Braga C, Ramos V, Vieira C, et al. New-onset atrial fibrillation during acute coronary syndromes: predictors and prognosis. *Rev Port Cardiol*. 2014.
 19. Cappato R. Atrial fibrillation complicating acute myocardial infarction: how should it be interpreted and how should it be treated and prevented? *Eur Heart J*. 2009;30(9):1035–7.
 20. Lau DH, Alasady M, Brooks AG, et al. New-onset atrial fibrillation and acute coronary syndrome. *Expert Rev Cardiovasc Ther*. 2010;8(7):941–8.
 21. Saczynski JS, McManus D, Zhou Z, et al. Trends in atrial fibrillation complicating acute myocardial infarction. *Am J Cardiol*. 2009;104(2):169–74.
 22. Zoni Berisso M, Carratino L, Ferroni A, et al. The relation between supraventricular tachyarrhythmias and left ventricular dysfunction after acute myocardial infarction. *Acta Cardiol*. 1988;43(6):689–701.
 23. Sugiura T, Iwasaka T, Takahashi N, et al. Atrial fibrillation in inferior wall Q-wave acute myocardial infarction. *Am J Cardiol*. 1991;67(13):1135–6.
 24. Kobayashi Y, Katoh T, Takano T, et al. Paroxysmal atrial fibrillation and flutter associated with acute myocardial infarction: hemodynamic evaluation in relation to the development of arrhythmias and prognosis. *Jpn Circ J*. 1992;56(1):1–11.
 25. Li-Saw-Hee FL, Blann AD, Gurney D, et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. *Eur Heart J*. 2001;22(18):1741–7.
 26. Raposeiras-Roubin S, García-Acuña JM, González-Juanatey JR. Letter by Raposeiras-Roubin et al. regarding article, mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. *Circulation*. 2011;124(18).
 27. Lam C-CS, Tse H-F, Siu C-W. Transient atrial fibrillation complicating acute myocardial infarction: a nuisance or a nemesis? *Thromb Haemost*. 2012;107(1):6–7.
 28. Lip GYH, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. *Thromb Haemost*. 2010;103(1):13–28.
 29. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. *Thromb Haemost*. 2011;106(4):569–71.
 30. Lopes RD, Li L, Granger CB, et al. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. *Am J Cardiol*. 2012;125(9):897–905.
 31. Fosbol EL, Wang TY, Li S, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. *Am Heart J*. 2013;166(5):864–70.
 32. Hess CN, Broderick S, Piccini JP, et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. *Am Heart J*. 2012;164(4):607–15.
 33. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet*. 2013;381(9872):1107–15.
 34. Siu C-W, Jim M-H, Ho H-H, et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. *Chest*. 2007;132(1):44–9.
 35. Zusman O, Amit G, Gilutz H, et al. The significance of new onset atrial fibrillation complicating acute myocardial infarction. *Clin Res Cardiol*. 2012;101(1):17–22.
 36. Bishara R, Telman G, Bahouth F, et al. Transient atrial fibrillation and risk of stroke after acute myocardial infarction. *Thromb Haemost*. 2011;106(5):877–84.
 37. Asanin MR, Milika AR, Vasiljevic ZM, et al. The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset atrial fibrillation. *Clin Cardiol*. 2009;32(8):467–70.